Dr. Bharath Takulapalli is Founder & CEO of INanoBio, a startup developing advanced technologies at the interface of nanotechnology, biology and machine learning (ML) for future Healthcare 2.0. He believes that, as a scientific community, we can preempt 90% of all diseases. Disease preemption implies detection in pre-disease stages, followed by early intervention and cure, before full disease onset. However, we do not have the technology tools to achieve this today. To contribute, at INanoBio we are developing two product platforms to extract 100x more information from systems biology (genotype and phenotype) than currently possible. First is a novel semiconductor nanopore transistor device to sequence the DNA 100X faster than state of art, at 1/10th the cost. The second is a first-of-kind multiplexed protein biosensor technology termed SPOC (sensor integrated proteome on chip) to study protein interactions at scale. INanoBio is based out of Menlo Park, California and Scottsdale, Arizona.
Clinical & Research Tools Showcase:
INanoBio is a DARPA funded company developing technologies at the interface of nanotechnology, biology and machine learning. In addition to FENT nanopore-transistor technology for 100x faster DNA sequencing, INanoBio is developing first-of-kind sensor integrated proteome on chip (SPOC) platform to screen protein interactions at scale.
Novel Solid-state Nanopore-transistor for 100x DNA Sequencing
INanoBio is developing novel Field Effect Nanopore Transistor (FENT) technology to sequence DNA 100x faster than state-of-art.
The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.